Related Articles
Continuous exposure of non‑small cell lung cancer cells with wild‑type EGFR to an inhibitor of EGFR tyrosine kinase induces chemoresistance by activating STAT3
<sup>18</sup>F‑FDG PET/CT SUV<sub>max</sub> and serum CEA levels as predictors for EGFR mutation state in Chinese patients with non‑small cell lung cancer
Comparison of the effectiveness of erlotinib, gefitinib, and afatinib for treatment of non‑small cell lung cancer in patients with common and rare EGFR gene mutations
Decreased human antigen R expression confers resistance to tyrosine kinase inhibitors in epidermal growth factor receptor-mutant lung cancer by inhibiting Bim expression
A peptide antigen derived from EGFR T790M is immunogenic in non‑small cell lung cancer